BetterLife Pharma Inc. (BETRF) Form 6-K — Sep 29, 2026
BetterLife Pharma reported a Q2 net loss of $2.09 million ($2.70 million for six months ended July 31, 2026), driven by share-based payments from 7.25 million stock options granted and warrant fair-value losses of $751,633. The company generated no revenue and carries an accumulated deficit of $122.8 million. The filing flags substantial doubt about going concern, with a $7.63 million working capital deficiency and only $973,593 in cash at July 31, 2026. Management noted it needed additional equity or debt financing to continue operations.
Key figures
- Revenue
- 0
- Total Debt
- 1970603
- Cash Position
- 973593
- Agents fee
- 9605879
- Current assets
- 2046481
- Accumulated deficit
- 122785512
- Current liabilities
- 9677800
- Warrants outstanding
- 75492639
- Clinical trial budget
- 105000000
- Offering gross proceeds
- 138748920
- Offering price per share
- 0.25
- Prefunded warrants issued
- 107958160
- Shares issued in offering
- 447041840
- Private placement apr 2026
- 499600
- Working capital deficiency
- 7631319
- Convertible debenture jun 2026
- 2000000
- Shares outstanding sept 29 2026
- 618007179
AI analysis
Red flags7 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.